Contract diagnostics outfit ResearchDx is making its way into India, counting on the boom in companion tests to drive demand for its services around the globe.
Global CRO Covance has struck up a deal to expand its diagnostics capabilities in oncology trials, partnering with NeoGenomics to bolster its anatomic pathology and specialty lab testing.
The Vietnamese government is looking to boost its share of the world's clinical research market, signing a deal with CRO giant Quintiles to get the ball rolling.
Catalent's new clinical supply operation in Shanghai is now open for business, giving the company a 31,000-square-foot operation it said offers broader capabilities than anything else in China.
CRO Medpace is on the block and could go for up to $1.2 billion, Reuters reports, as private equity owner CCMP Capital Advisors could be looking to cash out while the market for contract researchers remains bullish.
Quintiles was among the first CROs to jump into risk-based clinical trial monitoring, and now the world's largest contract researcher is stretching out its platform, offering adaptive services that span the whole development process.
Icon, like most of the world's largest CROs, is investing in high-tech adaptive trial monitoring, and the company's latest offering allows investigators to comb through huge dumps of lab data in real time, tracking trial trends as they happen.
WuXi PharmaTech, China's largest CRO, banked another strong revenue quarter thanks to escalating demand for clinical trials in its home country, and now the company is raising its annual profit expectations by about 7.6%.
Two months after merging with ReSearch Pharmaceutical Services to form the world's fourth-largest CRO, PRA is back on the buyer's block, snatching up the early-stage-focused CRI Lifetree.
Patient-recruitment specialist Synexus has opened an administrative center in Wroclaw, Poland, designed to oversee its expansion throughout Eastern Europe.
Cancer drug developer Cel-Sci ($CVM) wants at least $50 million in damages in from ex-CRO partner inVentiv Health, claiming breach of contract and fraud.
Quintiles declined to divulge financials when it signed up to buy Novella Clinical in August, but a regulatory filing reveals that the world's largest CRO spent $146.5 million upfront for the contractor, with more money on the line tied to milestones.
Deal-happy CMO Capsugel hasn't forgotten about its latest acquiree, planning to invest $20 million in Bend Research's spray-dried dispersion technology just a month after closing the buyout deal.
With three year's of back-and-forth with the FDA under its belt, contract drug developer AMRI has finally closed the book on an agency warning letter tied to its Burlington, MA, plant, ending a protracted saga that has cost the company millions.
As regulators the world over clamp down on biologics development, Covance has struck up a partnership with Pathoquest to offer next-generation sequencing-based tests for biotherapeutics.
Irish CRO Venn Life Sciences has agreed to trade nearly $1 million of stock for Germany's CRM Clinical Trials, a move that will stretch its reach into one of Europe's largest research markets.
Despite ongoing slowness in the market for early-stage research, preclinical specialist Charles River Laboratories boosted its revenue and income in the third quarter, a credit to its continued cost cuts and gains in market share, the company said.
Global CRO Covance rode a spike in demand for its late-stage services to a solid third quarter, increasing its revenue guidance and counting on a bump in business to light the way for Q4.
Quintiles, the world's largest CRO, is raising its annual profit projection as new partnerships and soaring income made up for flat revenue in the third quarter.
Outsourcing magnate inVentiv Health is padding its patient-adherence offerings, snapping up Catalina Health and merging the company with its Adheris subsidiary, a move it said creates the nation's largest provider of such services.